The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...
Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.
The biosimilars – which will be interchangeable with Sanofi's Lantus (insulin glargine ... prices of the originator insulin are around $329 per vial and $510 for five pens, according to ...
The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...
A vial of insulin costs about $8 to manufacture, researchers estimate. But Sanofi’s Lantus costs $292 per vial, Nordisk’s ...
that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions of its drug — Semglee cost $269 and a generic ...
A 10 ml vial of Sanofi's long-acting insulin Lantus first hit the US market at $34.81 a vial in 2001, according to data from Truven Health Analytics. Since 2014, the last time Sanofi raised the ...
28 days Prescribing information Insulin glargine (rDNA origin) vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days Prescribing information 70% insulin aspart protamine suspension ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback